Gynecologic Cancer News

Incomplete pregnancies appeared associated with reduced risk for invasive epithelial ovarian cancer, according to results of a study published in Journal of the National Cancer Institute.

Early post-therapy clearance of HPV appeared associated with improved survival among women with cervical cancer, according to results of a prospective study published in Cancer.

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

Final analysis results from the ICON8 trial confirmed that weekly dose-dense chemotherapy does not significantly improve progression-free survival or overall survival in patients with epithelial ovarian cancer.

KELIM, a model-based parameter from CA-125 kinetics, was an independent prognostic factor of progression-free survival for 5 years after first-line treatment in patients with ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

American Association for Cancer Research honored Lourdes A. Báezconde-Garbanati, PhD, with the AACR Distinguished Lectureship on the Science of Cancer Health Disparities.

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

Adding maintenance olaparib to bevacizumab provided a benefit beyond first progression, with a substantial second progression-free survival benefit, in patients with newly diagnosed, advanced high-grade ovarian carcinoma, according to data presented at ESMO Virtual Congress 2020.

After a 5-year follow-up, almost half of patients with newly diagnosed BRCA-mutated advanced ovarian cancer were progression-free after receiving 2 years of maintenance olaparib, according to data presented at ESMO Virtual Congress 2020.

Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.